The initial focus will be cross-sector as long as the other criteria are fulfilled. These are:

  1. Business to business technology i.e. enabling structural change to products and markets
  2. Sectors are life sciences, engineering and software
  3. Defensible innovation, i.e. some IPR or know-how that enables a sustainable advantage
  4. Late seed to Series B stage, i.e. revenue-generating (if not life-sciences) and technology de-risked with product-market fit validated
  5. Credible management team with both the commercial and technical skills required to drive value over the next two funding cycles
  6. Capital efficiency, i.e. no drug discovery or heavy manufacturing unless done in an IP-focused and capital-minimised way
  7. Financial possibility for 10x return within 3 to 7 years
  8. Boundary’s ability to add value, i.e. where specific expertise of the partners and/or appointed NED can be brought to bear
  9. Impact is demonstrable in one or more of the following ways:
    1. Potential to enrich the lives of at least 100 million people directly or indirectly in the long term
    2. Enrichment is defined as an improvement in the quality of life (i.e. therapies which improve how people live not just living longer or superfluous benefits), empowerment of lives i.e. enabling a greater democratising capability of skills
    3. Improve the sustainability of the environment with a global reach and a transformative potential factor

“An investment in knowledge pays the best interest.”

Benjamin Franklin 


If you want to know more about securing investment or becoming an investor get in touch.